Session » 2014 ACR/ARHP Annual Meeting

Abstract Number: 1949

Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus

Abstract Number: 576

Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axSpA) Are Related to Disease Duration

Abstract Number: 2349

Early Sympathectomy Inhibits Egress of Lymphocytes in Control and Arthritic Animals and Ameliorates Arthritic Disease

Abstract Number: 253

Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome

Abstract Number: 1873

Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study

Abstract Number: 97

Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data

Abstract Number: 968

Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation

Abstract Number: 1667

Probability of 3 and 6 Month Complete Response in Lupus Nephritis

Abstract Number: 2387

Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review

Abstract Number: 2596

Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort

Abstract Number: 2622

Systemic LUPUS Erythematosus in Spanish Males

Abstract Number: 3018

Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis

Abstract Number: 907

Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].